Novonesis stock lifts on 2026 guidance upgrade
Published on 08/25/2026 at 15:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novonesis stock (ISIN DK0060336014) traded close to DKK 450.60 on August 24, 2026, while the company lifted its 2026 organic sales growth outlook to 7% to 8% from 5% to 7%. The same update puts adjusted EBITDA margin at the upper end of 37% to 38%, giving investors a clearer view of the margin setup for the rest of the year.
Guidance reset
A recent guidance update reported on August 24, 2026, said Novonesis now expects a stronger top-line run rate after a solid first half. The midpoint of the sales range moved from 6% to 7.5%, a quantified upgrade that points to better volume and mix than previously assumed.
The margin guide matters just as much. An expected adjusted EBITDA margin at the top of the 37% to 38% range signals that the company is defending profitability while it pushes growth, which is a useful combination for a specialty biosolutions business.
What changed
The revised outlook ties back to sales momentum in the first half of 2026, when demand trends improved across the portfolio. In market terms, the latest home-market quote of DKK 450.60 sits alongside a raised full-year growth profile and a margin range that remains in the high-30s.
That comparison is important because the current share price now has to be measured against a more ambitious operating backdrop. A company guiding to 7% to 8% organic sales growth and a 37% to 38% adjusted EBITDA margin is signaling that incremental revenue should still flow through to earnings power.
Go deeper
One representative part of the business is detergent enzymes, where Novonesis helps manufacturers improve cleaning performance at lower wash temperatures. The same platform extends into food, agriculture, and bioenergy, where enzymes and microbes can improve yields, process efficiency, and product consistency.
Price and market view
The latest Copenhagen close of DKK 450.60 gives the stock a concrete reference point after the guidance reset. A raised outlook, a 7.5% midpoint for organic sales growth, and a margin guide at the top end of 37% to 38% are the key numbers now shaping the market debate.
Novonesis at a glance
Company: Novonesis A/S
ISIN: DK0060336014
Ticker: NSIS B
Exchange: Nasdaq Copenhagen
Price (as of August 24, 2026): DKK 450.60
Market cap: DKK 212.79 billion
Sector / Industry: Specialty Chemicals / Biosolutions
Index membership: OMX Copenhagen 25
Next earnings date: November 4, 2026
Novonesis stock now trades with a 2026 growth guide of 7% to 8% and an adjusted EBITDA margin expected at 37% to 38%, while the last Copenhagen close stood at DKK 450.60 on August 24, 2026.
